Excimer Light(308) Therapy for Resistant Alopecia Areata

Last updated: November 27, 2023
Sponsor: Assiut University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hair Loss

Alopecia

Treatment

excimer light

Clinical Study ID

NCT06149936
alopecia areata with excimer
  • Ages 18-55
  • All Genders

Study Summary

This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ● Having multiple patches of AA.
  • Duration of alopecia >1 year
  • No topical or systemic treatment for the last 4 months
  • Agreement to regular visits for treatment and follow-up.

Exclusion

Exclusion Criteria:

  • ● A single form of AA.
  • Alopecia for <1 year.
  • Being on other modalities of treatment.
  • Treatment within the last 4 months.
  • Photosensitive disorders.
  • Pregnancy or breastfeeding.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: excimer light
Phase:
Study Start date:
December 01, 2023
Estimated Completion Date:
December 30, 2024

Study Description

Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .